Prognostic Value of NRAS Gene for Survival of Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
- PMID: 30484984
- PMCID: PMC6318417
- DOI: 10.31557/APJCP.2018.19.11.3001
Prognostic Value of NRAS Gene for Survival of Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
Abstract
Introduction: NRAS gene is associated with malignant proliferation and metastasis of colorectal cancer (CRC). But its prognostic value on CRC is still unknown. The objective of this study is to perform a meta-analysis to obtain its prognostic value on survival of CRC patients. Methods: The systematic review and meta-analysis was designed, undertaken and reported using items from the PRISMA statement. Relevant articles were identified through PubMed (containing Medline), Embase, Web of Science databases and Google scholar search engines from their inception up to October 3, 2016. The articles about NRAS on prognosis of CRC patients were enrolled. The association between NRAS and CRC survival time (including overall survival [OS], progression-free survival [PFS], and disease-free survival [DFS]) was evaluated using hazard ratio (HR) with its corresponding 95% confidence interval (CI). Results: A total of fifteen articles were included. High-expression of NRAS was significantly associated with poor OS (HR: 1.36, 95% CI: 1.15–1.61), and poor PFS (HR: 1.75, 95% CI: 1.04–2.94). The combined HR of NRAS on DFS was 0.87 (95% CI: 0.37–2.03). Subgroup analysis showed that NRAS was significantly associated with poor OS for patients from Western countries (HR: 1.38, 95% CI: 1.09–1.73), but not for those from Asian countries. Conclusions: This meta-analysis demonstrate that NRAS gene could predict the poor prognosis for the CRC patients. More large-sample cohort studies are needed to further confirm this conclusion.
Keywords: NRAS gene; colorectal cancer; prognosis; meta-analysis.
Creative Commons Attribution License
Figures





Similar articles
-
Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations.Oncol Rep. 2014 Jul;32(1):50-6. doi: 10.3892/or.2014.3165. Epub 2014 May 6. Oncol Rep. 2014. PMID: 24806883
-
Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China.Curr Med Sci. 2021 Feb;41(1):118-126. doi: 10.1007/s11596-021-2326-1. Epub 2021 Feb 13. Curr Med Sci. 2021. PMID: 33582915
-
Hepatocyte growth factor is a prognostic marker in patients with colorectal cancer: a meta-analysis.Oncotarget. 2017 Apr 4;8(14):23459-23469. doi: 10.18632/oncotarget.15589. Oncotarget. 2017. PMID: 28423584 Free PMC article.
-
Log odds of positive lymph nodes as a novel prognostic predictor for colorectal cancer: a systematic review and meta-analysis.BMC Cancer. 2022 Mar 18;22(1):290. doi: 10.1186/s12885-022-09390-x. BMC Cancer. 2022. PMID: 35303818 Free PMC article.
-
Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: a systematic review and meta-analysis.BMC Gastroenterol. 2021 Jul 23;21(1):297. doi: 10.1186/s12876-021-01864-9. BMC Gastroenterol. 2021. PMID: 34301194 Free PMC article.
Cited by
-
Identification of Risk Factors for COVID-19-related Death using Machine Learning Methods.Tanaffos. 2022 Jan;21(1):54-62. Tanaffos. 2022. PMID: 36258910 Free PMC article.
-
Inoperable de novo metastatic colorectal cancer with primary tumour in situ: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre).Mol Clin Oncol. 2022 Feb;16(2):40. doi: 10.3892/mco.2021.2472. Epub 2021 Dec 21. Mol Clin Oncol. 2022. PMID: 35003738 Free PMC article.
-
Precision medicine for gastrointestinal cancer: Recent progress and future perspective.World J Gastrointest Oncol. 2020 Jan 15;12(1):1-20. doi: 10.4251/wjgo.v12.i1.1. World J Gastrointest Oncol. 2020. PMID: 31966910 Free PMC article. Review.
-
NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma.J Cancer Res Clin Oncol. 2022 Mar;148(3):565-575. doi: 10.1007/s00432-021-03842-w. Epub 2021 Nov 8. J Cancer Res Clin Oncol. 2022. PMID: 34746975 Free PMC article.
-
Rapid Malignant Transformation of Tubulovillous Adenoma, Initially Presenting as McKittrick-Wheelock Syndrome: A Case Report.Case Rep Oncol. 2023 Sep 4;16(1):818-826. doi: 10.1159/000531992. eCollection 2023 Jan-Dec. Case Rep Oncol. 2023. PMID: 37900797 Free PMC article.
References
-
- Amati B, Frank SR, Donjerkovic D, et al. Function of the c-Myc oncoprotein in chromatin remodeling and transcription. Biochim Biophys Acta. 2001;1471:135–45. - PubMed
-
- Andre T, Blons H, Mabro M, et al. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy:a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol. 2013;24:412–9. - PubMed
-
- Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683–91. - PubMed
-
- Boisvert-Adamo K, Aplin AE. Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene. 2008;27:3301–12. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous